(DXCM) DexCom - Overview
Stock: Glucose, Monitor, Sensor, Transmitter, App
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 43.7% |
| Relative Tail Risk | -18.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.39 |
| Alpha | -36.66 |
| Character TTM | |
|---|---|
| Beta | 0.985 |
| Beta Downside | 0.984 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.95% |
| CAGR/Max DD | -0.26 |
Description: DXCM DexCom December 17, 2025
DexCom, Inc. (NASDAQ:DXCM) designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management worldwide, selling directly to endocrinologists, physicians, and diabetes educators. Its flagship products include the G6 and G7 integrated CGM systems, the Dexcom Share remote-monitoring platform, the Real-Time API for third-party app integration, the ONE sensor aimed at replacing finger-stick testing, and the over-the-counter Stelo biosensor for pre-diabetes and Type 2 diabetes. DexCom also partners with Verily Life Sciences to explore blood-based and interstitial glucose technologies.
Key recent metrics: FY 2023 revenue reached approximately $3.2 billion, with the CGM segment growing at a ~12% CAGR, and DexCom holding roughly 30% of the U.S. CGM market share. In Q2 2024 the company reported $840 million in revenue and GAAP EPS of $0.96, beating consensus estimates. Sector drivers include rising global diabetes prevalence (projected >700 million patients by 2045), expanding payer reimbursement for CGM, and accelerating digital-health integration that fuels demand for APIs and remote-monitoring solutions.
For a deeper dive into DexCom’s valuation dynamics and how they compare to peers, you might find ValueRay’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 720.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.74 > 1.0 |
| NWC/Revenue: 41.71% < 20% (prev 63.94%; Δ -22.23% < -1%) |
| CFO/TA 0.19 > 3% & CFO 1.45b > Net Income 720.7m |
| Net Debt (685.3m) to EBITDA (1.22b): 0.56 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (407.4m) vs 12m ago -0.68% < -2% |
| Gross Margin: 59.01% > 18% (prev 0.62%; Δ 5840 % > 0.5%) |
| Asset Turnover: 65.19% > 50% (prev 62.23%; Δ 2.96% > 0%) |
| Interest Coverage Ratio: 51.47 > 6 (EBITDA TTM 1.22b / Interest Expense TTM 19.0m) |
Altman Z'' 4.03
| A: 0.25 (Total Current Assets 5.22b - Total Current Liabilities 3.34b) / Total Assets 7.50b |
| B: 0.29 (Retained Earnings 2.17b / Total Assets 7.50b) |
| C: 0.14 (EBIT TTM 978.0m / Avg Total Assets 6.93b) |
| D: 0.47 (Book Value of Equity 2.25b / Total Liabilities 4.77b) |
| Altman-Z'' Score: 4.03 = AA |
Beneish M -3.09
| DSRI: 0.94 (Receivables 1.11b/1.03b, Revenue 4.52b/3.95b) |
| GMI: 1.05 (GM 59.01% / 61.68%) |
| AQI: 0.91 (AQ_t 0.10 / AQ_t-1 0.11) |
| SGI: 1.14 (Revenue 4.52b / 3.95b) |
| TATA: -0.10 (NI 720.7m - CFO 1.45b) / TA 7.50b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of DXCM shares?
Over the past week, the price has changed by -4.20%, over one month by +0.11%, over three months by +20.60% and over the past year by -20.78%.
Is DXCM a buy, sell or hold?
- StrongBuy: 17
- Buy: 6
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DXCM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85.2 | 21.8% |
| Analysts Target Price | 85.2 | 21.8% |
| ValueRay Target Price | 69.8 | -0.2% |
DXCM Fundamental Data Overview February 03, 2026
P/E Forward = 29.4118
P/S = 6.2984
P/B = 10.4496
P/EG = 1.0207
Revenue TTM = 4.52b USD
EBIT TTM = 978.0m USD
EBITDA TTM = 1.22b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 1.23b USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 685.3m USD (from netDebt column, last quarter)
Enterprise Value = 27.64b USD (28.44b + Debt 2.52b - CCE 3.32b)
Interest Coverage Ratio = 51.47 (Ebit TTM 978.0m / Interest Expense TTM 19.0m)
EV/FCF = 26.03x (Enterprise Value 27.64b / FCF TTM 1.06b)
FCF Yield = 3.84% (FCF TTM 1.06b / Enterprise Value 27.64b)
FCF Margin = 23.51% (FCF TTM 1.06b / Revenue TTM 4.52b)
Net Margin = 15.96% (Net Income TTM 720.7m / Revenue TTM 4.52b)
Gross Margin = 59.01% ((Revenue TTM 4.52b - Cost of Revenue TTM 1.85b) / Revenue TTM)
Gross Margin QoQ = 60.48% (prev 59.53%)
Tobins Q-Ratio = 3.69 (Enterprise Value 27.64b / Total Assets 7.50b)
Interest Expense / Debt = 0.19% (Interest Expense 4.70m / Debt 2.52b)
Taxrate = 19.44% (68.5m / 352.3m)
NOPAT = 787.8m (EBIT 978.0m * (1 - 19.44%))
Current Ratio = 1.56 (Total Current Assets 5.22b / Total Current Liabilities 3.34b)
Debt / Equity = 0.92 (Debt 2.52b / totalStockholderEquity, last quarter 2.73b)
Debt / EBITDA = 0.56 (Net Debt 685.3m / EBITDA 1.22b)
Debt / FCF = 0.65 (Net Debt 685.3m / FCF TTM 1.06b)
Total Stockholder Equity = 2.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.40% (Net Income 720.7m / Total Assets 7.50b)
RoE = 29.82% (Net Income TTM 720.7m / Total Stockholder Equity 2.42b)
RoCE = 26.74% (EBIT 978.0m / Capital Employed (Equity 2.42b + L.T.Debt 1.24b))
RoIC = 16.21% (NOPAT 787.8m / Invested Capital 4.86b)
WACC = 8.78% (E(28.44b)/V(30.96b) * Re(9.54%) + D(2.52b)/V(30.96b) * Rd(0.19%) * (1-Tc(0.19)))
Discount Rate = 9.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.03%
[DCF Debug] Terminal Value 78.78% ; FCFF base≈851.1m ; Y1≈1.05b ; Y5≈1.79b
Fair Price DCF = 65.17 (EV 26.10b - Net Debt 685.3m = Equity 25.42b / Shares 390.0m; r=8.78% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 33.63 | EPS CAGR: -27.58% | SUE: -4.0 | # QB: 0
Revenue Correlation: 94.71 | Revenue CAGR: 15.77% | SUE: 1.47 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.48 | Chg30d=+0.001 | Revisions Net=+0 | Analysts=20
EPS next Year (2026-12-31): EPS=2.47 | Chg30d=-0.004 | Revisions Net=+0 | Growth EPS=+19.6% | Growth Revenue=+12.4%